GC
RLAY icon

Grace Capital’s Relay Therapeutics RLAY Stock Holding History

Grace Capital’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$5.62M Hold
183,112
– – 3.34% 4
2021
Q3 		$5.67M Hold
183,112
– – 3.48% 4
2021
Q2 		$6.7M Hold
183,112
– – 4.49% 1
2021
Q1 		$6.33M Buy
183,112
+18,723
+11% +$813K 4.03% 2
2020
Q4 		$6.83M Hold
164,389
– – 4.32% 2
2020
Q3 		$7M Buy
+164,389
New +$6.27M 5.43% 1

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Grace Capital's RLAY Position: Q4 2021 in Review

Grace Capital held its Relay Therapeutics (RLAY) position steady in Q4 2021 at 183,112 shares worth $5.62M. The position accounts for 3.34% of the portfolio, ranked #4.

Grace Capital first reported a position in RLAY in Q3 2020 and has held it in 6 quarters since. The position peaked at $7M in Q3 2020. 131 funds tracked by Wall St. Rank hold RLAY as of Q4 2021.

  • Grace Capital held 183,112 shares of Relay Therapeutics worth $5.62M as of Q4 2021.
  • Grace Capital left its Relay Therapeutics share count unchanged in Q4 2021.
  • Relay Therapeutics made up 3.34% of Grace Capital's portfolio in Q4 2021, its #4 holding.
  • Grace Capital first reported a position in Relay Therapeutics in Q3 2020 and has held it in 6 quarters since.
  • Grace Capital's Relay Therapeutics position peaked at $7M in Q3 2020.
  • 131 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2021.

Based on Grace Capital's 13F filing for Q4 2021, filed 2 Feb 2022.